Quantum BioPharma Ltd. (QNTM) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
QNTM Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Quantum BioPharma Ltd. (QNTM) trades at a price-to-earnings ratio of -0.6x, with a stock price of $4.88 and trailing twelve-month earnings per share of $-6.74.
Compared to the Healthcare sector median P/E of 22.2x, QNTM trades at a 103% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, QNTM trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our QNTM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
QNTM P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $390M | 28.8Lowest | 0.86Best | +51%Best | |
| $356B | 85.0 | - | -1% | |
| $533B | 38.2 | - | -58% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See QNTM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QNTM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QNTM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonQNTM — Frequently Asked Questions
Quick answers to the most common questions about buying QNTM stock.
Is QNTM stock overvalued or undervalued?
QNTM current P/E: -0.6x. 5-year average P/E: N/A. Percentile: N/A.
How does QNTM's valuation compare to peers?
Quantum BioPharma Ltd. P/E of -0.6x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is QNTM's PEG ratio?
QNTM PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.